Home › Research › Drug development
Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease
Whittington MD, Campbell JD, Rind D, Fluetsch N, Lin GA, Pearson SD.. Neurology, 2022-01-12
Topic: Amyloid, tau and blood-test diagnosis
Background and objectives Aducanumab was granted accelerated approval with a conflicting evidence base, near-unanimous Food and Drug Administration Advisory Committee vote to reject approval, and a widely criticized launch price of $56,000 per year. The objective of this analysis was to estimate its cost-effectiveness. Methods We developed a Markov model to compare aducanumab in addition to supportive care to supportive care alone over a lifetime horizon.
Key findings
- The objective of this analysis was to estimate its cost-effectiveness.
- Methods We developed a Markov model to compare aducanumab in addition to supportive care to supportive care alone over a lifetime horizon.
- Results were presented from both the health system and modified societal perspective.
- The model tracked the severity of disease and the care setting.
Why it matters
This analysis used a Markov model to estimate the cost-effectiveness of aducanumab plus supportive care compared with supportive care alone over a lifetime horizon. It addresses cost and value rather than whether the drug cures or prevents Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 49/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 50 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.3 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 4 / 6 | Cited 8.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 2 / 4 | Cited 24 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Steven D. Pearson: h-index 47 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California, San Francisco: institution h-index 1,915 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35022306) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Whittington, M. D., Campbell, J. D., Rind, D., Fluetsch, N., Lin, G. A., & Pearson, S. D. (2022). Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease. Neurology. https://doi.org/10.1212/wnl.0000000000013314
Vancouver
Whittington MD, Campbell JD, Rind D, Fluetsch N, Lin GA, Pearson SD. Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease. Neurology. 2022. doi:10.1212/wnl.0000000000013314. PMID: 35022306.
BibTeX
@article{whittington2022-35022306,
author = {Whittington, M. D. and Campbell, J. D. and Rind, D. and Fluetsch, N. and Lin, G. A. and Pearson, S. D.},
title = {{Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease}},
journal = {Neurology},
year = {2022},
doi = {10.1212/wnl.0000000000013314},
pmid = {35022306},
url = {https://doi.org/10.1212/wnl.0000000000013314}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in Drug development
Also tagged “double-blind”
783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.